CAMBRIDGE, Mass., June 01, 2024 Cullinan Therapeutics, Inc. , a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced positive initial data in.
Preliminary data from CLN-619 in combination with checkpoint inhibitor pembrolizumab show objective responses in patients with tumor types that are typically unresponsive to pembrolizumab, such as non-small cell lung cancer
Reabold Resources announces operational and corporate update energy-pedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from energy-pedia.com Daily Mail and Mail on Sunday newspapers.